JP2007524683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007524683A5 JP2007524683A5 JP2006553227A JP2006553227A JP2007524683A5 JP 2007524683 A5 JP2007524683 A5 JP 2007524683A5 JP 2006553227 A JP2006553227 A JP 2006553227A JP 2006553227 A JP2006553227 A JP 2006553227A JP 2007524683 A5 JP2007524683 A5 JP 2007524683A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- aryl
- compound
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 238000011282 treatment Methods 0.000 claims description 31
- 230000002265 prevention Effects 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102000019034 Chemokines Human genes 0.000 claims description 9
- 108010012236 Chemokines Proteins 0.000 claims description 9
- 208000028867 ischemia Diseases 0.000 claims description 9
- 230000000302 ischemic effect Effects 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 230000006806 disease prevention Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims 94
- 125000001072 heteroaryl group Chemical group 0.000 claims 39
- 125000003118 aryl group Chemical group 0.000 claims 38
- 125000003710 aryl alkyl group Chemical group 0.000 claims 30
- -1 sulfo, substituted sulfo , dihydroxyphosphoryl Chemical group 0.000 claims 30
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims 21
- 125000002252 acyl group Chemical group 0.000 claims 18
- 125000004442 acylamino group Chemical group 0.000 claims 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 18
- 125000003282 alkyl amino group Chemical group 0.000 claims 18
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims 18
- 125000004414 alkyl thio group Chemical group 0.000 claims 18
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 18
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 18
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 18
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 18
- 125000004663 dialkyl amino group Chemical group 0.000 claims 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims 18
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 18
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 18
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 12
- 150000003536 tetrazoles Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000004429 atom Chemical group 0.000 claims 9
- 150000001540 azides Chemical class 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical group ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 9
- 125000003107 substituted aryl group Chemical group 0.000 claims 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 230000010410 reperfusion Effects 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 0 **(C=C1)C2=C1C(C(*)=*O)=N**2 Chemical compound **(C=C1)C2=C1C(C(*)=*O)=N**2 0.000 description 3
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54476404P | 2004-02-13 | 2004-02-13 | |
| US54476504P | 2004-02-13 | 2004-02-13 | |
| US54476604P | 2004-02-13 | 2004-02-13 | |
| US54561604P | 2004-02-17 | 2004-02-17 | |
| US56250904P | 2004-04-14 | 2004-04-14 | |
| PCT/US2005/004236 WO2005079270A2 (en) | 2004-02-13 | 2005-02-11 | 2-substituted and 4-substituted aryl nitrone compouds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007524683A JP2007524683A (ja) | 2007-08-30 |
| JP2007524683A5 true JP2007524683A5 (enExample) | 2008-07-10 |
Family
ID=36607136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553227A Pending JP2007524683A (ja) | 2004-02-13 | 2005-02-11 | ２位置換および４位置換アリールニトロン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20050182060A1 (enExample) |
| EP (1) | EP1753714A4 (enExample) |
| JP (1) | JP2007524683A (enExample) |
| AR (1) | AR047671A1 (enExample) |
| CA (1) | CA2556270A1 (enExample) |
| TW (1) | TW200530163A (enExample) |
| WO (1) | WO2005079270A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050059638A1 (en) * | 2003-08-04 | 2005-03-17 | Kelly Michael G. | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders |
| GB0526257D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| EP1991540A1 (en) * | 2006-02-21 | 2008-11-19 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| JP4996575B2 (ja) | 2007-11-15 | 2012-08-08 | ローム アンド ハース カンパニー | ニトロンの製造 |
| CN101468970B (zh) * | 2008-04-25 | 2011-05-11 | 暨南大学 | 一种硝酮类化合物及其制备方法和在制药中的应用 |
| EP2356116A1 (en) * | 2008-11-20 | 2011-08-17 | OSI Pharmaceuticals, Inc. | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines |
| CA2772097C (en) | 2009-08-24 | 2019-04-30 | Hough Ear Institute | Methods for treating acute acoustic trauma |
| US8778969B2 (en) | 2009-11-07 | 2014-07-15 | Peter H Proctor | Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| EP2569315A1 (en) | 2010-05-14 | 2013-03-20 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| US9034926B2 (en) | 2010-12-30 | 2015-05-19 | Nicholas V. Perricone | Topical nitrone spin trap compositions for psoriasis |
| EP2710003A1 (en) | 2011-05-16 | 2014-03-26 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| US9708276B2 (en) | 2011-10-12 | 2017-07-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| BR112014012941B1 (pt) * | 2011-11-30 | 2019-04-09 | Dow Global Technologies Llc | Composição para cuidado pessoal, método cosmético para tratar pele, e, métodos para inibir a degradação de colágeno na pele e para reduzir os sinais visíveis de envelhecimento |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US10882834B2 (en) | 2013-09-20 | 2021-01-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compounds for treating prostate cancer |
| JP6654142B2 (ja) | 2014-03-07 | 2020-02-26 | ダウ グローバル テクノロジーズ エルエルシー | ニトロン化合物及びパーソナルケアにおけるその使用 |
| CN106458871B (zh) * | 2014-05-12 | 2018-12-28 | 陶氏环球技术有限责任公司 | 硝酮化合物和其在个人护理中的用途 |
| JP6734204B2 (ja) | 2014-06-30 | 2020-08-05 | ダウ グローバル テクノロジーズ エルエルシー | ポリマーニトロン及びパーソナルケアにおけるそれらの使用 |
| US10660851B2 (en) * | 2015-01-02 | 2020-05-26 | Rxos Medical | Polyfunctional radical scavenger hydrogel formulation |
| CN108024933B (zh) | 2015-03-20 | 2021-04-13 | 陶氏环球技术有限责任公司 | 硝酮抑制不饱和脂肪的氧化 |
| WO2016154018A1 (en) | 2015-03-20 | 2016-09-29 | Dow Global Technologies Llc | Nitrone inhibition of oxidation of unsaturated fats |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| WO2021203016A2 (en) * | 2020-04-03 | 2021-10-07 | The Regents Of The University Of California | Protein-protein interaction stabilizers |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| IL299612A (en) | 2020-07-02 | 2023-03-01 | Incyte Corp | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
| ES2924575A1 (es) * | 2021-03-25 | 2022-10-07 | Consejo Superior Investigacion | Derivados de quinolilnitronas para su uso en la prevencion y el tratamiento de la isquemia cerebral, ictus isquemico y enfermedades neurodegenerativas |
| EP4493558A1 (en) | 2022-03-17 | 2025-01-22 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7108691A (enExample) * | 1971-06-23 | 1972-12-28 | ||
| FR2243187B1 (enExample) * | 1973-09-10 | 1978-12-29 | Ile De France | |
| US3988229A (en) * | 1975-08-28 | 1976-10-26 | Eastman Kodak Company | Stabilized photopolymerizable polymeric compositions containing a photoinitiator and a nitrone derivative |
| GB8531839D0 (en) * | 1985-12-30 | 1986-02-05 | Wellcome Found | Aryl derivatives |
| IE59397B1 (en) * | 1985-03-16 | 1994-02-23 | Wellcome Found | New aryl derivatives |
| US5036157A (en) * | 1986-03-11 | 1991-07-30 | Burroughs Wellcome Co. | Aryl derivatives |
| US4972009A (en) * | 1989-08-18 | 1990-11-20 | Ciba-Geigy Corporation | Polymer stabilizers containing both hindered amine and nitrone moieties |
| US5622994A (en) * | 1989-10-17 | 1997-04-22 | Oklahoma Medical Research Foundation | Spin trapping pharmaceutical compositions and methods for use thereof |
| USRE35213E (en) * | 1989-10-17 | 1996-04-16 | Oklahoma Medical Research Foundation | Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration |
| US5681845A (en) * | 1989-10-17 | 1997-10-28 | Oklahoma Medical Research Foundation | DMPO spin trapping compositions and methods of use thereof |
| US5025032A (en) * | 1989-10-17 | 1991-06-18 | Oklahoma Medical Research Foundation | Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage |
| ES2044829T3 (es) * | 1989-10-17 | 1995-01-16 | Oklahoma Med Res Found | Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos. |
| US5036097A (en) * | 1989-10-17 | 1991-07-30 | Oklahoma Medical Research Foundation | Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration |
| US6002001A (en) * | 1991-06-18 | 1999-12-14 | Oklahoma Medical Research Foundation | Spin trapping pharmaceutical compositions and methods for use thereof |
| US20050107366A1 (en) * | 1991-06-18 | 2005-05-19 | Carney John M. | Spin trapping pharmaceutical compositions and methods for use thereof |
| JP3254007B2 (ja) * | 1992-06-09 | 2002-02-04 | 株式会社半導体エネルギー研究所 | 薄膜状半導体装置およびその作製方法 |
| US5475022A (en) * | 1993-10-18 | 1995-12-12 | Allergan, Inc. | Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity |
| US5455272A (en) * | 1993-10-22 | 1995-10-03 | Oklahoma Medical Research Foundation | Spin trap nitronyl hindered phenols |
| US5405967A (en) * | 1993-10-22 | 1995-04-11 | Oklahoma Medical Research Foundation | Spin-trap molecules 2-trifluoromethyl- of 5,5-dimethyl-1-dyrroline-N-oxide |
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| US5472032A (en) * | 1994-02-01 | 1995-12-05 | Winston; Patrick H. | Tire pressure maintenance system |
| AU7739796A (en) * | 1995-11-17 | 1997-06-11 | Florida International University | Azulenyl nitrone spin trapping agents, methods of making and using same |
| IL126725A0 (en) * | 1996-04-23 | 1999-08-17 | Centaur Pharmaceuticals Inc | Compositions comprising a nitrone compound for use in treating ocular inflammation |
| US5696152A (en) * | 1996-05-07 | 1997-12-09 | Wisconsin Alumni Research Foundation | Taxol composition for use as organ preservation and cardioplegic agents |
| WO1998003496A1 (en) * | 1996-07-19 | 1998-01-29 | Centaur Pharmaceuticals, Inc. | Furan nitrone compounds |
| ZA981934B (en) * | 1997-03-10 | 1999-09-06 | Rhone Poulenc Agrochimie | Pesticidal 1-aryl-3-iminopyrazoles. |
| ES2143920B1 (es) * | 1997-06-19 | 2000-12-16 | Batz S Coop Ltda | Gato ligero. |
| US6046232A (en) * | 1997-10-17 | 2000-04-04 | Centaur Pharmaceuticals, Inc. | α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same |
| NZ505757A (en) * | 1998-01-16 | 2002-09-27 | Centaur Pharmaceuticals Inc | Thioether furan nitrone compounds and pharmaceuticals thereof; useful for the treatment or prophylaxis of neurodegenerative, autoimmune and inflammatory conditions |
| CN1136212C (zh) * | 1998-01-16 | 2004-01-28 | 桑道药品有限公司 | 噻吩硝酮化合物 |
| JP2002506022A (ja) * | 1998-03-13 | 2002-02-26 | センター ファーマシューティカルズ， インコーポレイテッド | 新脈管形成の阻害 |
| US6271265B1 (en) * | 1998-05-19 | 2001-08-07 | Centaur Pharmaceuticals, Inc. | Amide therapeutics for the treatment of inflammatory bowel disease |
| WO1999059576A1 (en) * | 1998-05-19 | 1999-11-25 | Centaur Pharmaceuticals, Inc. | Aryl nitrone therapeutics for the treatment of inflammatory bowel disease |
| US6083989A (en) * | 1999-05-18 | 2000-07-04 | Centaur Pharmaceuticals, Inc. | Aryl nitrone therapeutics for the treatment of inflammatory bowel disease |
| WO2000003977A1 (en) * | 1998-07-17 | 2000-01-27 | Centaur Pharmaceuticals, Inc. | Alpha-(2-hydroxyphenyl) nitrone compounds, pharmaceutical compositions containing the same and their use for treating inflammation |
| UA66401C2 (en) * | 1998-12-02 | 2004-05-17 | Sentor Pharmaceuticals Inc | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same |
| US6730700B2 (en) * | 1998-12-02 | 2004-05-04 | Renovis, Inc. | 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same |
| US6339102B1 (en) * | 1999-06-09 | 2002-01-15 | The United States Of America As Represented By The Secretary Of The Army | Method and composition for treating and preventing retinal damage |
| AU1917201A (en) * | 1999-11-18 | 2001-05-30 | Centaur Pharmaceuticals, Inc. | Amide therapeutics and methods for treating inflammatory bowel disease |
| AU1917301A (en) * | 1999-11-18 | 2001-05-30 | Centaur Pharmaceuticals, Inc. | Aryl nitrone therapeutics and methods for treating inflammatory bowel disease |
| SE0000056D0 (sv) * | 2000-01-10 | 2000-01-10 | Astrazeneca Ab | Novel process |
| SE0000055D0 (sv) * | 2000-01-10 | 2000-01-10 | Centaur Pharmaceuticals Inc | Novel process |
| WO2001074349A1 (en) * | 2000-03-30 | 2001-10-11 | Oklahoma Medical Research Foundation | Butylnitrone containing compositons for inhibition of cancer development |
| WO2001080851A1 (en) * | 2000-04-21 | 2001-11-01 | United States Army Medical Research And Materiel Command | Method of treating, preventing or inhibiting central nervous system injuries and diseases |
| SE0001916D0 (sv) * | 2000-05-23 | 2000-05-23 | Astrazeneca Ab | Novel formulation |
| US6835754B2 (en) * | 2001-01-08 | 2004-12-28 | Renovis, Inc. | Use of aryl nitrone compounds in methods for treating neuropathic pain |
| WO2002078670A1 (en) * | 2001-03-02 | 2002-10-10 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
| FR2846969A1 (fr) * | 2002-11-08 | 2004-05-14 | Salles Jean Pierre | Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical |
| FR2846968B1 (fr) * | 2002-11-08 | 2005-02-04 | Salles Jean Pierre | Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone |
| US20050059638A1 (en) * | 2003-08-04 | 2005-03-17 | Kelly Michael G. | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders |
-
2005
- 2005-02-10 US US11/056,443 patent/US20050182060A1/en not_active Abandoned
- 2005-02-11 CA CA002556270A patent/CA2556270A1/en not_active Abandoned
- 2005-02-11 WO PCT/US2005/004236 patent/WO2005079270A2/en not_active Ceased
- 2005-02-11 EP EP05713280A patent/EP1753714A4/en not_active Withdrawn
- 2005-02-11 JP JP2006553227A patent/JP2007524683A/ja active Pending
- 2005-02-14 TW TW094104239A patent/TW200530163A/zh unknown
- 2005-02-14 AR ARP050100522A patent/AR047671A1/es unknown
-
2009
- 2009-07-15 US US12/503,664 patent/US20100168112A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007524683A5 (enExample) | ||
| TWI245770B (en) | Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate | |
| EP2429986B1 (en) | Haloalkyl heteroaryl benzamide compounds | |
| ES2435799T3 (es) | Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales | |
| JP5393679B2 (ja) | アレナウイルス感染症を治療するための抗ウイルス薬 | |
| CA3139977A1 (en) | Peptidomimetics for the treatment of coronavirus and picornavirus infections | |
| JP2009502743A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| JP2021191784A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2002540156A (ja) | 抗ウイルス治療用チアジアゾリルウレアまたはチオウレア誘導体 | |
| US20120108592A1 (en) | Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses | |
| JP2006515858A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| US7205413B2 (en) | Solvates and polymorphs of ritonavir and methods of making and using the same | |
| TW200916103A (en) | Therapeutic compositions and methods | |
| JP2018531987A5 (enExample) | ||
| JP2005527576A5 (enExample) | ||
| JP2019526546A5 (enExample) | ||
| BRPI0609375A2 (pt) | formas farmacêuticas com caracterìsticas farmacocinéticas aperfeiçoadas | |
| TW200817416A (en) | 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors | |
| JP2008516925A (ja) | 双極性障害および随伴症状の治療 | |
| WO2023052772A1 (en) | Amido derivatives for use in the treatment of rna viral infections | |
| JPWO2022253936A5 (enExample) | ||
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral |